1. CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL. (12th June 2019) Authors: Jacobsen, E.; Ďuraš, J.; Ardeshna, K.; Cherry, M.; Offner, F.; Mayer, J.; Bijou, F.; Tani, M.; Musuraca, G.; Merli, M.; Marasca, R.; Weaver, D.T.; Lustgarten, S.; Youssoufian, H.; Zinzani, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 400 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THE ELDERLY PROJECT BY THE FONDAZIONE ITALIANA LINFOMI: A PROSPECTIVE COMPREHENSIVE GERIATRIC ASSESSMENT (CGA) OF 1353 ELDERLY PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Spina, M.; Merli, F.; Puccini, B.; Cavallo, F.; Cabras, M.G.; Fabbri, A.; Angrilli, F.; Zilioli, V.R.; Marino, D.; Balzarotti, M.; Ladetto, M.; Cox, M.C.; Petrucci, L.; Arcari, A.; Gini, G.; Chiappella, A.; Hohaus, S.; Musuraca, G.; Merli, M.; Sartori, R. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 248 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. LENALIDOMIDE AND RITUXIMAB (ReRi) AS FRONT LINE THERAPY OF ELDERLY FRAIL PATIENTS WITH DIFFUSE LARGE B‐CELLS LYMPHOMA. FIRST PLANNED INTERIM ANALYSIS OF A PHASE II STUDY OF THE FONDAZIONE ITALIANA LINFOMI (FIL). (12th June 2019) Authors: Gini, G.; Tani, M.; Bassan, R.; Tucci, A.; Ballerini, F.; Sampaolo, M.; Merli, F.; Re, F.; Annibali, O.; Liberati, A.; Visco, C.; Arcari, A.; Storti, S.; Fabbri, A.; Musuraca, G.; Zilioli, V.; Cox, M.; Luminari, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. (12th June 2019) Authors: Ghia, P.; Pluta, A.; Wach, M.; Lysak, D.; Kozak, T.; Simkovic, M.; Kaplan, P.; Kraychok, I.; Illes, A.; De La Serna, J.; Dolan, S.; Campbell, P.; Musuraca, G.; Jacob, A.; Avery, E.J.; Lee, J.H.; Chen, T.; Liang, W.; Patel, P.; Jurczak, W. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OBINUTUZUMAB‐MINICHOP FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA. A STUDY OF THE FONDAZIONE ITALIANA LINFOMI. (June 2017) Authors: Merli, F.; Luminari, S.; Salvi, F.; Cavallo, F.; Gini, G.; Musuraca, G.; Gaidano, G.; Cellini, C.; Merli, M.; Ferrari, A.; Molinari, A.; Liberati, A.M.; Conconi, A.; Matteucci, P.; Pozzi, S.; Musso, M.; Mammi, C.; Monaco, F.; Ferrero, S.; Tucci, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. UPDATED RESULTS OF THE FIL "MIRO" STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA. (17th June 2021) Authors: Pulsoni, A.; Tosti, M. E.; Ferrero, S.; Luminari, S.; Dondi, A.; Liberati, A. M.; Cenfra, N.; Renzi, D.; Zanni, M.; Boccomini, C.; Ferreri, A. J.; Rattotti, S.; Zilioli, V. R.; Bernuzzi, P.; Bolis, S.; Musuraca, G.; Nassi, L.; Perrone, T.; Stelitano, C.; Anastasia, A. Journal: Hematological oncology Issue: Volume 39(2021)Supplement 2 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. S208: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING (ID) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE GLOBAL PHASE 2 STUDY TIDAL. (23rd June 2022) Authors: Zelenetz, A.; Jurczak, W.; Ribrag, V.; Linton, K.; Collins, G.; Lopéz-Jiménez, J.; Reddy, N.; Mengarelli, A.; Phillips, T.; Musuraca, G.; Sheehy, O.; Li, J.; Xu, W.; Azoulay, M.; Ghalie, R.; Zinzani, P. L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PB1986: ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET. (23rd June 2022) Authors: Cerchione, C.; Nappi, D.; Pareto, A. E.; Ronconi, S.; Cangini, D.; Ceccolini, M.; Musuraca, G.; Catalano, L.; Martinelli, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1858 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PB1985: CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS' ERA. (23rd June 2022) Authors: Cerchione, C.; Nappi, D.; Pareto, A. E.; Ronconi, S.; Cangini, D.; Ceccolini, M.; Musuraca, G.; Catalano, L.; Martinelli, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1857 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP. (23rd June 2022) Authors: Ghia, P.; Pluta, A.; Wach, M.; Lysak, D.; Simkovic, M.; Kriachok, I.; Illes, A.; de la Serna, J.; Dolan, S.; Campbell, P.; Musuraca, G.; Jacob, A.; Avery, E.; Lee, J. H.; Usenko, G.; Wang, M. H.; Yu, T.; Jurczak, W. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 566 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗